NEW YORK (GenomeWeb) – Saying that it does not believe its Chemical and Applied Markets division can achieve "acceptable financial performance" in the next two years, Bruker today said that it plans to sell and/or restructure certain parts of the CAM business, resulting in an expected 200 to 250 layoffs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.